Progress in gene therapy for primary immunodeficiencies using lentiviral vectors

Current Opinion in Allergy and Clinical Immunology

Volumn 14, Issue 6, 2014, Pages 527-534

  Sauer, Aisha V ^a   Di Lorenzo, Biagio ^a   Carriglio, Nicola ^a   Aiuti, Alessandro ^a,b  

^a SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Gene therapy; Lentiviral vector; Primary immunodeficiency; Severe combined immunodeficiency

Indexed keywords

LENTIVIRUS VECTOR;

ADENOSINE DEAMINASE DEFICIENCY; CHRONIC GRANULOMATOUS DISEASE; HUMAN; IMMUNE DEFICIENCY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEVERE COMBINED IMMUNODEFICIENCY; VIRAL GENE THERAPY; WISKOTT ALDRICH SYNDROME; X LINKED SEVERE COMBINED IMMUNODEFICIENCY; CLINICAL TRIAL (TOPIC); COMMON VARIABLE IMMUNODEFICIENCY; GENE THERAPY; GENE VECTOR; GENETICS; IMMUNOLOGY; LENTIVIRINAE; WISKOTT-ALDRICH SYNDROME; X-LINKED COMBINED IMMUNODEFICIENCY DISEASES;

CLINICAL TRIALS AS TOPIC; COMMON VARIABLE IMMUNODEFICIENCY; GENETIC THERAPY; GENETIC VECTORS; HUMANS; LENTIVIRUS; WISKOTT-ALDRICH SYNDROME; X-LINKED COMBINED IMMUNODEFICIENCY DISEASES;

EID: 84926189337     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0000000000000114     Document Type: Review

References (97)

1. Montini E, Cesana D, Schmidt M, et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 2009; 119:964-975.
2. Montini E, Cesana D, Schmidt M, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 2006; 24:687-696.
3. Sauer AV, Aiuti A. New insights into the pathogenesis of adenosine deaminase-severe combined immunodeficiency and progress in gene therapy. Curr Opin Allergy Clin Immunol 2009; 9:496-502.
4. Gene therapy clinical trial worldwide, provided by the Journal of Gene Medicine [internet]. http://www.wiley.com/legacy/wileychi/genmed/clinical/. [Accessed June 2014]
5. Bousfiha AA, Jeddane L, Ailal F, et al. Primary immunodeficiency diseases worldwide: more common than generally thought. J Clin Immunol 2013; 33:1-7.
6. Chiriaco M, Farinelli G, Capo V, et al. Dual-regulated lentiviral vector for gene therapy of X-linked chronic granulomatosis. Mol Ther 2014; 22:1472-1483.
7. ClinicalTrials.gov [internet]. Bethesda (MD): National Library of Medicine (US). https://clinicaltrials.gov/. [Accessed June 2014]
8. Riviere J, Hauer J, Poirot L, et al. Variable correction of Artemis deficiency by I-Sce1-meganuclease-assisted homologous recombination in murine hemato-poietic stem cells. Gene Ther 2014; 21:529-532.
9. van Til NP, Sarwari R, Visser TP, et al. Recombination-activating gene 1 (Rag1)-deficient mice with severe combined immunodeficiency treated with lentiviral gene therapy demonstrate autoimmune Omenn-like syndrome. J Allergy Clin Immunol 2014; 133:1116-1123.
10. Rivat C, Booth C, Alonso-Ferrero M, et al. SAP gene transfer restores cellular and humoral immune function in a murine model of X-linked lymphoproliferative disease. Blood 2013; 121:1073-1076.
11. Passerini L, Mel ER, Sartirana C, et al. CD4(+) T cells from IPEX patients convert into functional and stable regulatory T cells by FOXP3 gene transfer. Sci Transl Med 2013; 5:215ra174.
12. Biffi A, Montini E, Lorioli L, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 2013; 341:1233158.
13. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009; 326:818-823.
14. Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 2010; 467:318-322.
15. Aiuti A, Cattaneo F, Galimberti F, et al. Long-term safety and efficacy of gene therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency. New Engl J Med 2009; 360:447-458.
16. Williams DA, Thrasher AJ. Concise review: lessons learned from clinical trials of gene therapy in monogenic immunodeficiency diseases. Stem Cells Transl Med 2014; 3:636-642.
17. Cesana D, Sgualdino J, Rudilosso L, et al. Whole transcriptome characterization of aberrant splicing events induced by lentiviral vector integrations. J Clin Invest 2012; 122:1667-1676.
18. Moiani A, Paleari Y, Sartori D, et al. Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts. J Clin Invest 2012; 122:1653-1666.
19. Ramezani A, Hawley TS, Hawley RG. Combinatorial incorporation of enhancer-blocking components of the chicken beta-globin 5'HS4 and human T-cell receptor alpha/delta BEAD-1 insulators in self-inactivating retroviral vectors reduces their genotoxic potential. Stem Cells 2008; 26:3257-3266.
20. Emery DW. The use of chromatin insulators to improve the expression and safety of integrating gene transfer vectors. Hum Gene Ther 2011; 22:761-774.
21. Evans-Galea MV, Wielgosz MM, Hanawa H, et al. Suppression of clonal dominance in cultured human lymphoid cells by addition of the cHS4 insulator to a lentiviral vector. Mol Ther 2007; 15:801-809.
22. Li CL, Xiong D, Stamatoyannopoulos G, et al. Genomic and functional assays demonstrate reduced gammaretroviral vector genotoxicity associated with use of the cHS4 chromatin insulator. Mol Ther 2009; 17:716-724.
23. Cesana D, Ranzani M, Volpin M, et al. Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo. Mol Ther 2014; 22:774-785.
24. Zhang F, Frost AR, Blundell MP, et al. A ubiquitous chromatin opening element (UCOE) confers resistance to DNA methylation-mediated silencing of lentiviral vectors. Mol Ther 2010; 18:1640-1649.
25. Van Maele B, De Rijck J, De Clercq E, et al. Impact of the central polypurine tract on the kinetics of human immunodeficiency virus type 1 vector transduction. J Virol 2003; 77:4685-4694.
26. Zufferey R, Donello JE, Trono D, et al. Woodchuck hepatitis virus posttran-scriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol 1999; 73:2886-2892.
27. Ramezani A, Hawley TS, Hawley RG. Lentiviral vectors for enhanced gene expression in human hematopoietic cells. Mol Ther 2000; 2:458-469.
28. Barde I, Laurenti E, Verpi S, et al. Lineage- and stage-restricted lentiviral vectors for the gene therapy of chronic granulomatous disease. Gene Ther 2011; 18:1087-1097.
29. Friedrich RI, Nopora K, Brocker T. Transcriptional targeting of B cells with viral vectors. Eur J Cell Biol 2012; 91:86-96.
30. Santilli G, Almarza E, Brendel C, et al. Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells. Mol Ther 2011; 19:122-132.
31. Brown BD, Venneri MA, Zingale A, et al. Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat Med 2006; 12:585-591.
32. Brown BD, Gentner B, Cantore A, et al. Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat Biotechnol 2007; 25:1457-1467.
33. Cronin J, Zhang XY, Reiser J. Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther 2005; 5:387-398.
34. Yang L, Bailey L, Baltimore D, et al. Targeting lentiviral vectors to specific cell types in vivo. Proc Natl Acad Sci U S A 2006; 103:11479-11484.
35. Ochs HD, Thrasher AJ. The Wiskott-Aldrich syndrome. J Allergy Clin Immunol 2006; 117:725-738; quiz 739.
36. Marangoni F, Trifari S, Scaramuzza S, et al. WASP regulates suppressor activity of human and murine CD4(+)CD25(+)FOXP3(+) natural regulatory T cells. J Exp Med 2007; 204:369-380.
37. Moratto D, Giliani S, Bonfim C, et al. Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hema-topoietic cell transplantation in the period 1980-2009: an international collaborative study. Blood 2011; 118:1675-1684.
38. Farinelli G, Capo V, Scaramuzza S, et al. Lentiviral vectors for the treatment of primary immunodeficiencies. J Inherit Metab Dis 2014; 37:525-533.
39. Boztug K, Schmidt M, Schwarzer A, et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N EnglJ Med 2010; 363:1918-1927.
40. Candotti F. Gene transfer into hematopoietic stem cells as treatment for primary immunodeficiency diseases. IntJ Hematol 2014; 99:383-392.
41. Braun CJ, Botzug K, Parazynski A, et al. Gene therapy for Wiskott-Aldrich syndrome-long-term efficacy and genotoxicity. Sci Transl Med 2014; 6:227ra33.
42. Petrella A, Doti I, Agosti V, et al. A 5' regulatory sequence containing two Ets motifs controls the expression of the Wiskott-Aldrich syndrome protein (WASP) gene in human hematopoietic cells. Blood 1998; 91:4554-4560.
43. Dupre L, Marangoni F, Scaramuzza S, et al. Efficacy of gene therapy for Wiskott-Aldrich syndrome using a WAS promoter/cDNA-containing lentiviral vector and nonlethal irradiation. Hum Gene Ther 2006; 17:303-313.
44. Aiuti A, Biasco L, Scaramuzza S, et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 2013; 341:1233151.
45. Galy A, Roncarolo MG, Thrasher AJ. Development of lentiviral gene therapy for Wiskott Aldrich syndrome. Expert Opin Biol Ther 2008; 8:181-190.
46. Astrakhan A, Sather BD, Ryu BY, et al. Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott-Aldrich syndrome. Blood 2012; 119:4395-4407.
47. Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002; 296:2410-2413.
48. Hirschhorn R, Candotti F. Immunodeficiency due to defects of purine metabolism. In: Ochs HD, Smith IE, Puck JM, editors. Primary immunodeficiency diseases. Oxford, United Kingdom: Oxford University Press; 2006. pp. 169-196.
49. Booth C, Hershfield M, Notarangelo L, et al. Management options for adenosine deaminase deficiency; proceedings of the EBMT satellite workshop (Hamburg, March 2006). Clin Immunol 2007; 123:139-147.
50. Hershfield MS, Buckley RH, Greenberg ML, et al. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med 1987; 316:589-596.
51. Sauer AV, Brigida I, Carriglio N, et al. Autoimmune dysregulation and purine metabolism in adenosine deaminase deficiency. Front Immunol 2012; 3:265.
52. Gaspar HB, Cooray S, Gilmour KC, et al. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med 2011; 3:97ra80.
53. Candotti F, Shaw KL, Muul L, et al. Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood 2012; 120:3635-3646.
54. Cassani B, Montini E, Maruggi G, et al. Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapy. Blood 2009; 114:3546-3556.
55. Mortellaro A, Hernandez RJ, Guerrini MM, et al. Ex vivo gene therapy with lentiviral vectors rescues adenosine deaminase (ADA)-deficient mice and corrects their immune and metabolic defects. Blood 2006; 108:2979-2988.
56. Carbonaro DA, Jin X, Petersen D, et al. In vivo transduction by intravenous injection of a lentiviral vector expressing human ADA into neonatal ADA gene knockout mice: a novel form of enzyme replacement therapy for ADA deficiency. Mol Ther 2006; 13:1110-1120.
57. Gaspar, HB, Buckland K, Rivati C, et al., Immunological and metabolic correction after lentiviral vector mediated haematopoietic stem cell gene therapy for ADA deficiency. In: American Society of Gene & Cell Therapy: ASGCT2014, Molecular Therapy: Washington. pp. 106.
58. Carbonaro DA, Zhang L, Jin X, et al. Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency. Mol Ther 2014; 22:607-622.
59. Griffith LM, Cowan MJ, Notarangelo LD, et al. Primary Immune Deficiency Treatment Consortium (PIDTC) report. J Allergy Clin Immunol 2014; 133:335-347.
60. Seger RA. Chronic granulomatous disease: recent advances in pathophysiology and treatment. Neth J Med 2010; 68:334-340.
61. Grez M, Reichenbach J, Schwable J, et al. Gene therapy of chronic granulomatous disease: the engraftment dilemma. Mol Ther 2011; 19:28-35.
62. Stein S, Ott MG, Schultze-Strasser S, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010; 16:198-204.
63. Brendel C, Mueller-Kuller U, Schultze-Strasser S, et al. Physiological regulation of transgene expression by a lentiviral vector containing the A2UCOE linked to a myeloid promoter. Gene Ther 2012; 19:1018-1029.
64. Williams S, Mustoe T, Mulcahy T, et al. CpG-island fragments from the HNRPA2B1/CBX3 genomic locus reduce silencing and enhance transgene expression from the hCMV promoter/enhancer in mammalian cells. BMC Biotechnol 2005; 5:17.
65. Kaufmann KB, Buning H, Galy A, et al. Gene therapy on the move. EMBO Mol Med 2013; 5:1642-1661.
66. Thrasher, A.J., Gene therapy for primary immunodeficiencies. In: European Society for Gene and Cell Therapy: ESGCT2013, Human Gene Therapy: Madrid. pp. 20.
67. Noguchi M, Yi H, Rosenblatt HM, et al. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 1993; 73:147-157.
68. Buckley RH, Schiff SE, Schiff RI, et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 1999; 340:508-516.
69. Herzog RW. Gene therapy for SCID-X1: round 2. Mol Ther 2010; 18:1891.
70. Gaspar HB, Cooray S, Gilmour KC, et al. Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med 2011; 3:97ra79.
71. Hacein-Bey-Abina S, Hauer J, Lim A, et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2010; 363:355-364.
72. Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008; 118:3132-3142.
73. Howe SJ, Mansour MR, Schwarzwaelder K, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008; 118:3143-3150.
74. Thornhill SI, Schambach A, Howe SJ, et al. Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency. Mol Ther 2008; 16:590-598.
75. Qasim W, Gennery AR. Gene therapy for primary immunodeficiencies: current status and future prospects. Drugs 2014; 74:963-969.
76. Touzot F, Hacein-Bey-Albina S, Fucher A, et al. Gene therapy for inherited immunodeficiency. Expert Opin Biol Ther 2014; 14:789-798.
77. Huston MW, Van Til NP, Visser TP, et al. Correction of murine SCID-X1 by lentiviral gene therapy using a codon-optimized IL2RG gene and minimal pretransplant conditioning. Mol Ther 2011; 19:1867-1877.
78. Zhou S, Mody D, De Ravin SS, et al. A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells. Blood 2010; 116:900-908.
79. De Ravin, SS, Moir S, Theobald N, et al., Lentivector gene therapy with nonmyeloablative conditioning restores igg production in young adults with SCID-X1. In American Society of Gene & Cell Therapy: ASGCT2014, Molecular Therapy: Washington. pp. 106.
80. Arumugam PI, Higashimoto T, Urbinati F, et al. Genotoxic potential of lineage-specific lentivirus vectors carrying the beta-globin locus control region. Mol Ther 2009; 17:1929-1937.
81. Modlich U, Navarro S, Zychlinski D, et al. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther 2009; 17:1919-1928.
82. Almarza D, Bussadori G, Navarro M, et al. Risk assessment in skin gene therapy: viral-cellular fusion transcripts generated by proviral transcriptional read-through in keratinocytes transduced with self-inactivating lentiviral vectors. Gene Ther 2011; 18:674-681.
83. Ranzani M, Cesana D, Bartholomae CC, et al. Lentiviral vector-based insertional mutagenesis identifies genes associated with liver cancer. Nat Methods 2013; 10:155-161.
84. Maldarelli F, Wu X, Su L, et al. HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science 2014; 345:179-183.
85. Wagner TA, McLaughlin S, Garg K, et al. HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science 2014; 345:570-573.
86. Fischer A. Gene therapy: repair and replace. Nature 2014; 510:226-227.
87. Urnov FD, Rebar EJ, Holmesi MC, et al. Genome editing with engineered zinc finger nucleases. Nat Rev Genet 2010; 11:636-646.
88. Joung JK, Sander JD. TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol 2013; 14:49-55.
89. Sander JD, Joung JK. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol 2014; 32:347-355.
90. Zou J, Sweeney CL, Chou BK, et al. Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting. Blood 2011; 117:5561-5572.
91. Lombardo A, Cesana D, Genovese P, et al. Site-specific integration and tailoring of cassette design for sustainable gene transfer. Nat Methods 2011; 8:861-869.
92. Lombardo A, Genovese P, Beausejour CM, et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol 2007; 25:1298-1306.
93. Li H, Haurigot V, Doyon Y, et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 2011; 475:217-221.
94. Genovese P, Schiroli G, Escobar G, et al. Targeted genome editing in human repopulating haematopoietic stem cells. Nature 2014; 510:235-240.
95. Riddell J, Gazit R, Garrison BS, et al. Reprogramming committed murine blood cells to induced hematopoietic stem cells with defined factors. Cell 2014; 157:549-564.
96. Corrigan-Curay J, Cohen-Haguenauer O, O'Reilly M, et al. Challenges in vector and trial design using retroviral vectors for long-term gene correction in hematopoietic stem cell gene therapy. Mol Ther 2012; 20:1084-1094.
97. Aiuti A, Cossu G, De Felipe P, et al. The committee for advanced therapies' of the European Medicines Agency reflection paper on management of clinical risks deriving from insertional mutagenesis. Hum Gene Ther Clin Dev 2013; 24:47-54.